Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cisen Pharmaceutical Co., Ltd. (603367.SS)
Jining, CN
Cisen Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, manufacturing and distributing a diverse portfolio of chemical drug preparations and healthcare products to both domestic and international markets. Founded in 1998 and based in Jining, People's Republic of China, the company offers an extensive range of chemical drug solutions. These include medications for liver diseases, antitumor and supportive treatments, nutritional supplements, contrast agents, antibiotics, digestive system remedies, polypropylene ampoules, and topical preparations. Additionally, their product line encompasses sedation and anesthesia agents, cardiovascular drugs, treatments for cough and asthma, immunomodulators, and various infusion and therapeutic infusion products. The company officially changed its name to Cisen Pharmaceutical Co., Ltd. in 2011, having previously operated as Shandong Lukang Cisen Pharmaceutical Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.82% | -3.12% | -10.23% | -20.00% | -25.35% | -19.40% | -2.31% | -12.15% | +4.65% | -16.86% | -16.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-13.5% Q1'26: -7.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-17.0% Q1'26: -9.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+7.3% Q1'26: +24.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.9% Q1'26: +18.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+7.2% ★ Q1'26: +17.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.4% ★ Q1'26: +0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.86× ★ Q1'26: 0.27× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|
| Revenue |
3.81B
est: 3.75B (+1.5%)
|
4.11B
est: 4.74B (-13.1%)
|
3.98B
est: 4.93B (-19.3%)
|
3.44B
est: 5.37B (-35.8%)
|
| EBITDA |
678.17M
est: 547.77M (+23.8%)
|
629.75M
est: 691.15M (-8.9%)
|
683.33M
est: 714.19M (-4.3%)
|
466.28M
est: 777.33M (-40.0%)
|
| EBIT |
500.58M
est: 350.05M (+43.0%)
|
465.27M
est: 441.68M (+5.3%)
|
466.89M
est: 441.43M (+5.8%)
|
270.96M
est: 480.46M (-43.6%)
|
| Net Income |
503.54M
|
514.58M
|
508.91M
est: 584.05M (-12.9%)
|
421.25M
est: 647.44M (-34.9%)
|
| SGA |
1.23B
est: 1.38B (-10.3%)
|
1.47B
est: 1.74B (-15.1%)
|
1.37B
est: 1.76B (-22.5%)
|
1.11B
est: 1.92B (-42.0%)
|
| EPS |
1.11
|
1.14
|
1.12
est: 1.29 (-13.2%)
|
0.93
est: 1.43 (-35.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 275.1K | 0.39% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 52.1K | 0.46% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 73.5K | 0.29% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 43.9K | 0.28% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 393.98 | 0.44% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Liushan Hao | Deputy GM & Director | — | male |
| Xianglin Zhang | Deputy General Manager | — | male |
| Xiaoting Cui | Deputy General Manager | — | male |
| Xinbing Xu | Financial Director, Board Secretary, Accounting Supervisor & Director | — | male |
| Xiu Lian Lu | Deputy GM & Director | — | female |
| Ze Lin Ren | Deputy General Manager | — | male |
| Zhenxin Du | GM & Chairman | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603367.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
